Middle East & Africa Recombinant Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Middle East and Africa Recombinant Albumin Market size is expected to reach US$ 23,251.6 Million by 2031 from US$ 13,677.0 Million in 2024. The market is estimated to record a CAGR of 7.9% from 2025 to 2031.

Executive Summary and Middle East and Africa Recombinant Albumin Market Analysis:

The Middle East and Africa recombinant albumin market is expanding due to increasing healthcare demands and the rising prevalence of liver and kidney diseases. According to the World Health Organization (WHO), liver disease cases in the region reached approximately 1.2 million in 2022, with countries such as Egypt and South Africa reporting significant incidences. The Egyptian Ministry of Health indicated a 15% rise in hospital admissions for liver-related conditions from 2022 to 2023, emphasizing the urgent need for effective treatments. In 2024, new recombinant albumin products were expected to be introduced, supported by approvals from the Saudi Food and Drug Authority (SFDA) and the South African Health Products Regulatory Authority (SAHPRA), which were promoting innovative therapeutic options. Additionally, the Gulf Cooperation Council (GCC) has been investing in biotechnology research, aiming to enhance local production capabilities. These regulatory advancements, combined with the increasing adoption of recombinant albumin in critical care and surgical settings, are driving market growth. Thus, the convergence of rising disease prevalence, supportive regulatory frameworks, and ongoing product innovations creates a conducive environment for market growth.

Middle East & Africa Recombinant Albumin Market: Strategic Insights

Middle East and Africa Recombinant Albumin Market Segmentation Analysis:

• By Source, the Middle East and Africa Recombinant Albumin Market is segmented into Human Recombinant Albumin, Bovine Recombinant Albumin, and Other Sources. The Human Recombinant Albumin segment dominated the market in 2024.
• By Application, the Middle East and Africa Recombinant Albumin Market is segmented into Excipient in Biotherapeutics and Vaccines, Cell Culture, Drug Delivery, Diagnostics, and Other Applications. The Excipient in Biotherapeutics and Vaccines segment dominated the market in 2024.
• By End User, the Middle East and Africa Recombinant Albumin Market is segmented into Pharmaceutical and Biotechnology Companies, Research Institutes, Hospitals and Diagnostic Laboratories, and Others End Users. The Pharmaceutical and Biotechnology Companies segment dominated the market in 2024.

Middle East & Africa Recombinant Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The Middle East & Africa Recombinant Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Middle East and Africa Recombinant Albumin Market Outlook

A major opportunity for recombinant albumin in the Middle East lies in reducing dependence on imported plasma-derived human serum albumin (HSA) while addressing the growing burden of chronic diseases that frequently require albumin therapy. The region has witnessed rising rates of liver disease, diabetes, chronic kidney disease, and critical care admissions, particularly in Gulf Cooperation Council (GCC) countries. According to the International Diabetes Federation, the Middle East and North Africa (MENA) region is among the fastest-growing diabetes markets globally, with millions of adults affected and at increased risk of complications requiring hospitalization and albumin supplementation. In addition, increasing cases of liver cirrhosis, non-alcoholic fatty liver disease (NAFLD), and sepsis-related complications are contributing to higher albumin utilization across hospitals. To strengthen healthcare self-sufficiency and reduce reliance on imported plasma products, countries such as Saudi Arabia and the United Arab Emirates are investing in biotechnology manufacturing and healthcare localization initiatives. As demand for albumin-based therapies continues to rise, recombinant human albumin offers a scalable, pathogen-free alternative to plasma-derived products, supporting long-term supply security and improved access to critical care treatments across the region.

Middle East and Africa Recombinant Albumin Market Country Insights

By country, the Middle East and Africa Recombinant Albumin Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East and Africa. Saudi Arabia held the largest share in 2024.

The increasing prevalence of chronic illnesses in Saudi Arabia has created a strong need for better medical treatments which particularly apply to liver diseases. The national disease control authority estimated that hepatitis C and other liver diseases affected nearly 2.7% of the population in 2022 which created a substantial public health burden. The requirement for effective and easily accessible treatments has reached urgent levels because forecasts predict a 10% rise in chronic liver disease cases that will occur before 2024.

The Kingdom is currently experiencing major changes in its healthcare system. The Saudi Food and Drug Authority introduced regulatory reforms which have created faster approval processes for biopharmaceuticals that now enable companies to bring new recombinant therapies to markets more quickly. The domestic pharmaceutical industry released its first recombinant albumin products in 2023 which doctors use to treat cirrhosis patients.The government maintains its focus on advancing healthcare services and funding biotechnology projects which support the objectives of Vision 2030. The strategic initiatives support research activities while establishing local production capabilities which create a business environment that enables continuous expansion of the Saudi biopharmaceutical industry.

Middle East and Africa Recombinant Albumin Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc, CSL Ltd, Merck KGaA, Sartorius AG, Akron Biotech, HiMedia Laboratories Pvt Ltd, InVitria, Medxbio Pte Ltd, Lazuline Biotech Private Limited, and Cyagen Biosciences.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East and Africa Recombinant Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise